ArticleFrontiers in bioengineering and biotechnology2025
Superparamagnetic polyhemoglobin-tyrosinase nanocapsules: a novel biotherapeutic with enhanced tumor suppression with control by external magnetic field.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Magnetic nanorobots in oncology: From targeted drug delivery to smart theranostic systems.Materials today. Bio · 2026Review
- Artificial Cells: Perspective on Reconstructing Biological Cells and "Out of the Box" Innovations.Chembiochem : a European journal of chemical biology · 2026Review
- Article
- Biodegradable Polylactide Nanocapsules Containing Quercetin for In Vitro Suppression of Mouse B16F10 and Human Sk-Mel-28 Melanoma Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Our recent study shows nanobiotherepeutic Polyhemoglobin-Tyrosinase-Nanocapsules (PolyHb-Tyr-Nano) have strong anti-tumor abilities in multiple cancer lines. However, despite their tumor inhibitory potential, some internal tumor sites can be difficult to reach. Methods: In this paper, based on Chang's original finding that artificial cells containing magnetic material can be controlled by external magnetic fields, using nanoprecipitation methods, we modified this biotechnological nanotherapeutic with superparamagnetic properties, which shown to be attracted and guided by external magnets. Results: By fluorescence microscopy, we show that external magnetic field improved the local deposition of the nanorobotic superparamagnetic PolyHb-Tyr-nano at the tumor microenvironment (TME), significantly preventing their clearance, to stay at the tumor site despite repeated washings. This allowed time for them to enter the tumor cells to act intracellularly. In cell proliferation tests and tumor migration study, their tumor inhibitory action on the four cancer cell lines: Hepa 1-6 liver cancer line, A549 lung cancer line, HeLa cervical cancer line, and MCF7 breast cancer line are also retained effective, a low cell viability and tumor migration was observed. Furthermore, the addition of superparamagnetic property has enhanced the nanocapsules uptake and tumor inhibitory abilities, significantly improved their drug effect on tumor cells. Via cell viability test, PAL assay, oxidative stress detection, and mitochondria membrane potential studies, the PolyHb-Tyr-nano has shown improved tumor killing, by amino acid reduction, reactive oxygen species (ROS) generation, to mitochondria activity reduction in the presence of external magnetic fields. Discussion: Our results showed the efficacy of the nanorobotic superparamagnetic PolyHb-Tyr-nano on anti-tumor effect in multiple cancer lines. This novel nanobiotherapeutic has the potential for future cancer therapy, and can enhance drug localization, targeted delivery, and combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.